To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

Solvay Pharmaceuticals

Overview

The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Schizophrenia Schizoaffective Disorder

Interventions

BifeprunoxDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Schizophrenia or Schizoaffective disorder * 18-55 years Exclusion Criteria: * Subjects who are acutely psychotic * Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia * Subjects at significant risk of suicide * Subjects with a seizure disorder

Locations (1)

Site 1

Wichita, Kansas, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.